Sequencing of over 100,000 individuals identifies multiple genes and rare variants associated with Crohns disease susceptibility

Competing Interest Statement

M.A. is consulting for or part of the advisory board for AbbVie Inc, Bellatrix Pharmaceuticals, Bristol Myers Squibb, Eli Lilly Pharmaceuticals, Gilead, Janssen Ortho, LLC, and Prometheus Biosciences; teaching, lecturing, or speaking at Alimentiv, Arena Pharmaceuticals, Janssen, Prime CME, Takeda Pharmaceuticals. A.B is an employee of Regeneron and owns stock in Regeneron. O.M.D. has served in the IBD fellowship funding committee for Pfizer and has a funded research project by Pfizer. H.K. receives grant funding from Takeda and Pfizer and has received consulting fees from Takeda. A.P. is a member of Astra Zenecas Genomics Advisory Board. M.A.R. is on the SAB of 54gene and has advised BioMarin, Third Rock Ventures, MazeTx, and Related Sciences. D.P.B.M. has consulted for Takeda, Boehringer Ingelheim, Palatin Technologies, Bridge Biotherapeutics, Pfizer, and Gilead. Cedars-Sinai and D.P.B.M. have financial interests in Prometheus Biosciences, a company which has access to the data and specimens in Cedars-Sinais MIRIAD Biobank (including the Cedars-Sinai data and specimens used in this study) and seeks to develop commercial products. C.A.A. has received consultancy fees from Genomics plc and BridgeBio Inc. M.J.D. is a founder of Maze Therapeutics.

Funding Statement

This research was funded in whole, or in part, by the US National Institutes of Health Grants U54HG003067 and 5UM1HG008895, the Wellcome Trust Grant 206194, and with support from The Leona M. & Harry B. Helmsley Charitable Trust 2015PGIBD001. We thank the Broad Institute Genomics Platform for genomic data generation efforts and the Stanley Center for Psychiatric Research at the Broad Institute for supporting control sample aggregation. M.A.R. is in part supported by the NHGRI of the NIH under award R01HG010140 (M.A.R.) and an NIH Center for Multi- and Trans-ethnic Mapping of Mendelian and Complex Diseases grant (5U01HG009080). H.H. acknowledges support from NIDDK K01DK114379 and the Stanley Center for Psychiatric Research. Individual studies contributing to this meta-analysis acknowledge support from NIH grants DK062432, DK087694, K23DK117054, R01DK111843, P01DK094779, R01HG010140, 5U01HG009080, and DK062420, National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) Grants P01DK046763, U01DK062413, and R01DK104844. We acknowledge the Crohns & Colitis Foundations IBD Plexus Program ȓ the results published here are in part based on data obtained from the IBD Plexus program of the Crohns & Colitis Foundation. We acknowledge the contribution of the Oxford IBD cohort study and the Oxford GI biobank, which are supported by the NIHR Oxford Biomedical Research Centre. We acknowledge individual study support from FNRS (Fond National de la Recherche Scientifique, Belgium), the NIHR Newcastle Biomedical Research Centre, the Charles Wolfson Charitable Trust, the Canadian Institute for Health Research Grants SPOR-RN279389358033, the Academy of Finland Centre of Excellence in Complex Disease Genetics (312074, 336824), the German Excellence Initiative EXC 2167 and IMI Programm of the EU ("3TR"), the European Regional Development Fund 01.2.2-LMT-K-718-04-0003 and philanthropic support from Martin Schlaff, James L. Brooks and Ma. The German IBD Consortium would like to acknowledge the CCIM that receives infrastructure support from the DFG Cluster of Excellence "Precision Medicine in Chronic Inflammation" (PMI). The Cedars-Sinai IBD study was supported by the Cedars-Sinai MIRIAD IBD Biobank. The MIRIAD IBD Biobank receives funding from the Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, National Institute of Diabetes and Digestive and Kidney Disease Grants P01DK046763 and U01DK062413, and The Leona M. and Harry B. Helmsley Charitable Trust. The FINRISK controls were part of the FINRISK studies supported by THL (formerly KTL: National Public Health Institute) through budgetary funds from the government, with additional funding from institutions such as the Academy of Finland, the European Union, ministries and national and international foundations and societies to support specific research purposes. The UK/IRL controls were collected and sequenced with support from the Neuroscience Research Charitable Trust, the Central London NHS (National Health Service) Blood Transfusion Service and the National Institute of Health Research (NIHR) funded Mental Health Research Network. The Epi25 Collaborative was supported by the NHGRI Centers for Common Disease Genomics Genomics (CCDG) grant (UM1HG008895) and the Stanley Center for Psychiatric Research. The NIMH Controls were supported by a cooperative agreement grant funded by the National Institute of Mental Health (U01MH100233, U01MH100209, U01MH100229, U01MH100239). Participants in the INTERVAL randomised controlled trial were recruited with the active collaboration of NHS Blood and Transplant England (www.nhsbt.nhs.uk [nhsbt.nhs.uk]), which has supported field work and other elements of the trial. DNA extraction and genotyping were co-funded by the National Institute for Health Research (NIHR), the NIHR BioResource (http://bioresource.nihr.ac.uk [bioresource.nihr.ac.uk]) and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014)[*]. Sequencing was supported by the Wellcome Trust grant number 206194. The academic coordinating centre for INTERVAL was supported by core funding from the: NIHR Blood and Transplant Research Unit in Donor Health and Genomics (NIHR BTRU-2014-10024), UK Medical Research Council (MR/L003120/1), British Heart Foundation (SP/09/002; RG/13/13/30194; RG/18/13/33946) and NIHR Cambridge BRC (BRC-1215-20014). This work was supported by Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Study Protocol 2013P002634, The Broad Institute Study of Inflammatory Bowel Disease Genetics​, undergoes annual continuing review by the Mass General Brigham Human Research Committee (MGBHRC) Institutional Review Board (IRB) of Mass General Brigham. ​Ethical approval was given on January 27, 2021, for this study. Mass General Brigham IRB, Mass General Brigham, 399 Revolution Drive, Suite 710, Somerville, MA 02145

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes